治疗性疫苗市场规模、份额及成长分析（按产品、技术及地区）- 2025-2032 年产业预测

2023 年全球治疗性疫苗市场规模价值为 537.1 亿美元，预计将从 2024 年的 593.5 亿美元增长到 2032 年的 1319.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 10.5%。

由于疫苗的应用越来越增强免疫反应并帮助慢性疾病患者的康復，治疗性疫苗市场预计将大幅成长。慢性病盛行率的上升以及对创新疫苗研发投入的增加预计将对销售产生正面影响。此外，人们对预防保健的认识不断增强以及对个人化医疗的需求预计将在未来几年进一步推动治疗性疫苗的采用。然而，研发的复杂性和对疗效有限的担忧等挑战可能会阻碍市场的发展。为了克服这些障碍，治疗性疫苗公司有机会透过将其产品与各种免疫疗法和精准医疗策略相结合来探索协同效应。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

治疗性疫苗市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 成瘾疫苗
• 自体免疫疾病疫苗
• 感染疾病疫苗
• 神经系统疫苗

治疗性疫苗市场规模（依技术及复合年增长率） (2025-2032)

• 市场概况
• 自体疫苗​​接种
• 同源疫苗

治疗性疫苗市场规模（按地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Sanofi SA（France）
• Pfizer Inc.（United States）
• Moderna, Inc.（United States）
• BioNTech SE（Germany）
• Bavarian Nordic A/S（Denmark）
• Medigene AG（Germany）
• Arbutus Biopharma Corporation（Canada）
• Inovio Pharmaceuticals, Inc.（United States）
• Dynavax Technologies Corporation（United States）
• Agenus Inc.（United States）
• Heat Biologics, Inc.（United States）
• Northwest Biotherapeutics, Inc.（United States）
• ImmunoCellular Therapeutics, Ltd.（United States）
• Advaxis, Inc.（United States）
• OncoSec Medical Incorporated（United States）
• Vical Incorporated（United States）
• Celldex Therapeutics, Inc.（United States）
• Altimmune, Inc.（United States）

结论和建议

Global Therapeutic Vaccines Market size was valued at USD 53.71 billion in 2023 and is poised to grow from USD 59.35 billion in 2024 to USD 131.92 billion by 2032, growing at a CAGR of 10.5% during the forecast period (2025-2032).

The therapeutic vaccine market is poised for significant growth, driven by the increasing application of these vaccines in enhancing immune response and aiding recovery in chronic disease patients. The rising prevalence of chronic illnesses, coupled with escalating investments in the research and development of innovative vaccines, is anticipated to positively impact sales. Additionally, the growing awareness of preventive healthcare and the demand for personalized medicine are expected to further boost therapeutic vaccine adoption in the coming years. However, challenges such as the complexity of R&D and concerns over limited efficacy may hinder market development. To navigate these obstacles, therapeutic vaccine companies have the opportunity to explore synergies by integrating their offerings with various immunotherapies and precision medicine strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Therapeutic Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Therapeutic Vaccines Market Segments Analysis

Global Therapeutic Vaccines Market is segmented by Products, Technology and Region. Based on Products, the market is segmented into Addiction Vaccines, Autoimmune Disease Vaccines, Infectious Disease Vaccines and Neurological Disease Vaccines. Based on Technology, the market is segmented into Autologous vaccines and Allogeneic vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Therapeutic Vaccines Market

The rising prevalence of infectious and chronic diseases globally has heightened awareness of the importance of preventive healthcare among the population. This growing consciousness is projected to positively influence the market for therapeutic vaccines, as more individuals recognize the value of vaccination in preventing illness. As a result, the demand for innovative therapeutic vaccine solutions is expected to surge, driving sales and expanding market opportunities. This shift in perspective towards proactive health measures underscores the critical role that therapeutic vaccines play in enhancing public health outcomes and addressing global health challenges.

Restraints in the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market faces significant constraints due to the extensive and demanding approval and testing protocols that these vaccines must navigate before being authorized for patient use worldwide. This intricate and time-consuming process can considerably delay the entry of therapeutic vaccines into the market, hindering the overall growth potential of the industry. As a result, the lengthy timeline from development to market availability can create obstacles for companies, stalling innovation and limiting the timely delivery of potentially life-saving treatments to patients in need across the globe.

Market Trends of the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market is witnessing a significant shift towards the integration of vaccines within immunotherapy frameworks, aimed at enhancing treatment efficacy for cancer patients. Vendors are increasingly focusing on developing innovative products that tailor immune responses to specific tumor types, thereby optimizing therapeutic outcomes. This trend reflects a growing recognition of the importance of personalized immunotherapy, where therapeutic vaccines are designed to modify and strengthen the body's immune system against cancer more effectively. As research and clinical applications advance, this strategic alignment is expected to drive substantial growth in the therapeutic vaccines sector, positioning it as a key component in the fight against cancer.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Therapeutic Vaccines Market Size by Products & CAGR (2025-2032)

• Market Overview
• Addiction Vaccines
• Autoimmune Disease Vaccines
• Infectious Disease Vaccines
• Neurological Disease Vaccines

Global Therapeutic Vaccines Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Autologous vaccines
• Allogeneic vaccines

Global Therapeutic Vaccines Market Size & CAGR (2025-2032)

• North America (Products, Technology)
  • US
  • Canada
• Europe (Products, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products, Technology)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medigene AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbutus Biopharma Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heat Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Northwest Biotherapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunoCellular Therapeutics, Ltd. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advaxis, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoSec Medical Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vical Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altimmune, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations